GFP/Luc Reporter Cell Line - B-cpap

The B-CPAP cell line is a highly characterized human model of papillary thyroid carcinoma (PTC), originally established from a tumor of a female patient. It is extensively utilized in endocrine oncology research because it faithfully retains key genetic alterations driving human thyroid cancer, most notably the endogenous BRAF V600E mutation. The GFP/Luc Reporter Cell Line - B-CPAP is a sophisticated, stably transfected derivative that has been explicitly engineered to co-express both Green Fluorescent Protein (GFP) and firefly luciferase (Luc). This robust dual-labeling construct ensures continuous, high-level expression of both functional reporter genes across sequential in vitro passages. Importantly, this stable integration is achieved without compromising the fundamental morphological characteristics, mutational profile, or the intrinsic tumorigenic capacity of the original parental B-CPAP cells.

The incorporation of this dual-reporter system significantly broadens the experimental utility of the B-CPAP model for translational thyroid cancer research. For in vitro studies, the distinct GFP expression allows researchers to easily visualize cellular dynamics, quantify proliferation rates, and isolate specific cellular subpopulations using standard fluorescence microscopy and flow cytometry techniques. For in vivo applications, the robust luciferase activity acts as the foundation for non-invasive, longitudinal tracking of tumor growth via bioluminescence imaging (BLI). Because it is a human-derived cell line, the B-CPAP-GFP/Luc model is typically engrafted into immunocompromised mice (such as athymic nude or NSG models) to establish subcutaneous or orthotopic xenografts. This reporter line is exceptionally valuable for evaluating the therapeutic efficacy of targeted pharmacological agents, such as selective BRAF inhibitors, as well as novel targeted therapies and radiotherapeutics. By facilitating the real-time, quantitative monitoring of tumor burden and metastatic spread in living subjects, it highly optimizes experimental workflows in preclinical thyroid oncology.